Abbott Laboratories $ABT Stock: Eurizon Capital SGR S.p.A. Cuts Stake

Eurizon Capital SGR S.p.A. lowered its stake in Abbott Laboratories (NYSE:ABT – Free Report) by 6.0% in the 3rd quarter, Holdings Channel reports. The firm owned 1,254,659 shares of the healthcare product maker’s stock after selling 80,618 shares during the quarter. Eurizon Capital SGR S.p.A.’s holdings in Abbott Laboratories were worth $124,718,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. BlackRock Inc. lifted its holdings in shares of Abbott Laboratories by 4.6% in the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock worth $13,843,610,000 after buying an additional 6,769,518 shares in the last quarter. State Street Corp boosted its position in shares of Abbott Laboratories by 1.7% in the second quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker’s stock valued at $7,343,246,000 after acquiring an additional 1,350,766 shares during the period. Bank of America Corp DE purchased a new position in Abbott Laboratories during the second quarter valued at approximately $1,603,607,000. Deutsche Bank AG grew its stake in Abbott Laboratories by 18.6% during the second quarter. Deutsche Bank AG now owns 16,706,669 shares of the healthcare product maker’s stock valued at $1,515,963,000 after acquiring an additional 2,614,965 shares in the last quarter. Finally, Legal & General Group Plc purchased a new position in Abbott Laboratories during the second quarter valued at approximately $1,082,524,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on ABT shares. Royal Bank Of Canada decreased their target price on shares of Abbott Laboratories from $130.00 to $125.00 and set an “outperform” rating on the stock in a report on Thursday, October 22nd. JPMorgan Chase & Co. cut their price target on shares of Abbott Laboratories from $120.00 to $118.00 and set an “overweight” rating for the company in a report on Thursday, October 22nd. Wells Fargo & Company upped their price target on shares of Abbott Laboratories from $112.00 to $119.00 and gave the stock an “overweight” rating in a report on Thursday, October 22nd. BTIG Research lowered their price objective on Abbott Laboratories from $134.00 to $125.00 and set a “buy” rating on the stock in a research report on Thursday, October 22nd. Finally, Argus downgraded Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday, October 27th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $118.32.

Get Our Latest Research Report on ABT

Abbott Laboratories Stock Down 1.9%

Shares of NYSE ABT opened at $107.23 on Friday. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $132.02. The company has a current ratio of 1.45, a quick ratio of 1.00 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $185.71 billion, a price-to-earnings ratio of 40.01, a PEG ratio of 1.92 and a beta of 0.54. The business has a 50-day moving average of $103.94 and a 200-day moving average of $101.74.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, hitting the consensus estimate of $1.42. The company had revenue of $13.01 billion for the quarter, compared to analysts’ expectations of $12.99 billion. Abbott Laboratories had a net margin of 9.75% and a return on equity of 18.04%. Abbott Laboratories’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same period in the prior year, the business earned $1.30 earnings per share. Sell-side analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. Abbott Laboratories’s payout ratio is currently 94.03%.

Insider Activity at Abbott Laboratories

In other news, EVP Mary Moreland sold 3,500 shares of the stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $116.00, for a total value of $406,000.00. Following the transaction, the executive vice president owned 100,791 shares of the company’s stock, valued at $11,691,756. This represents a 3.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.46% of the stock is owned by insiders.

About Abbott Laboratories

(Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.

See Also

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.